Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 4 | 10 |
| List of Tables | 7 | 4 |
| List of Figures | 11 | 3 |
| Oncology Therapeutics Market to 2017 - Introduction | 14 | 2 |
| GBI Research Report Guidance | 15 | 1 |
| Oncology Therapeutics Market to 2017 - Market Overview | 16 | 12 |
| Revenue Forecasts for Oncology Therapeutics Market | 16 | 1 |
| Revenue | 16 | 2 |
| Revenue Share by Geography | 18 | 2 |
| Brand and Generic Share | 20 | 2 |
| Annual Cost of Treatment | 22 | 1 |
| Treatment Usage Patterns | 23 | 2 |
| Drivers and Barriers for Oncology Therapeutics Market | 25 | 1 |
| Drivers | 25 | 1 |
| Increasing Prevalence of Cancer | 25 | 1 |
| Rapid Uptake of Targeted Therapeutics in Key Indications | 25 | 1 |
| Barriers | 26 | 1 |
| Patent Expirations and Entry of Generics Pose a Serious Problem for Primary Manufacturers | 26 | 1 |
| Moderate Growth in the US Market | 26 | 1 |
| Reimbursement Restrictions on Certain Oncology Drug Classes Restricts Market Growth | 27 | 1 |
| Oncology Therapeutics Market to 2017 - Geographical Landscape | 28 | 12 |
| The US | 28 | 1 |
| Revenue | 28 | 1 |
| Annual Cost of Treatment | 29 | 1 |
| Treatment Usage Patterns | 30 | 2 |
| Top Five Countries of Europe | 32 | 1 |
| Revenue | 32 | 1 |
| Annual Cost of Treatment | 33 | 1 |
| Treatment Usage Patterns | 34 | 2 |
| Japan | 36 | 1 |
| Revenue | 36 | 1 |
| Annual Cost of Treatment | 37 | 1 |
| Treatment Usage Patterns | 38 | 2 |
| Oncology Therapeutics Market to 2017 - Therapeutic Landscape | 40 | 90 |
| Breast Cancer | 40 | 1 |
| Introduction | 40 | 2 |
| Survival Rates by Stage | 42 | 1 |
| Symptoms | 42 | 1 |
| Treatment Flow | 43 | 3 |
| Revenue | 46 | 1 |
| Geographical Segmentation | 47 | 2 |
| Brand and Generic Share | 49 | 1 |
| Annual Cost of Treatment | 50 | 1 |
| Treatment Usage Patterns | 51 | 2 |
| Drivers and Barriers for Breast Cancer Therapeutics Market | 53 | 1 |
| Drivers | 53 | 1 |
| Barriers | 54 | 1 |
| Colorectal Cancer | 55 | 1 |
| Introduction | 55 | 1 |
| Survival Rates by Stage | 56 | 1 |
| Symptoms | 56 | 1 |
| Treatment Flow | 57 | 3 |
| Revenue | 60 | 1 |
| Geographical Segmentation | 61 | 2 |
| Brand and Generic Share | 63 | 1 |
| Annual Cost of Treatment | 64 | 1 |
| Treatment Usage Patterns | 65 | 2 |
| Drivers and Barriers for Colorectal Cancer Therapeutics Market | 67 | 1 |
| Drivers | 67 | 1 |
| Barriers | 67 | 1 |
| Non-Hodgkin s Lymphoma Therapeutics Market | 68 | 1 |
| Introduction | 68 | 1 |
| Survival Rates by Stage | 69 | 1 |
| Symptoms | 70 | 1 |
| Treatment Flow | 70 | 1 |
| Revenue | 71 | 2 |
| Geographical Segmentation | 73 | 1 |
| Generic Share | 74 | 1 |
| Annual Cost of Treatment | 75 | 1 |
| Treatment Usage Patterns | 76 | 1 |
| Drivers and Barriers for Non-Hodgkin s Lymphoma Market | 77 | 1 |
| Drivers | 77 | 1 |
| Barriers | 78 | 1 |
| Non-Small Cell Lung Cancer (NSCLC) | 78 | 1 |
| Introduction | 78 | 1 |
| Survival Rates by Stage | 79 | 1 |
| Symptoms | 79 | 1 |
| Treatment Flow | 80 | 2 |
| Revenue | 82 | 1 |
| Geographic Segmentation | 83 | 2 |
| Generic Share | 85 | 1 |
| Annual Cost of Treatment | 86 | 1 |
| Treatment Usage Patterns | 87 | 1 |
| Drivers and Barriers for NSCLC Therapeutics Market | 88 | 1 |
| Drivers | 88 | 1 |
| Barriers | 89 | 1 |
| Prostate Cancer Therapeutics Market | 89 | 1 |
| Introduction | 89 | 1 |
| Survival Rates | 90 | 1 |
| Symptoms | 90 | 1 |
| Treatment Flow | 90 | 2 |
| Revenue | 92 | 1 |
| Geographical Segmentation | 93 | 1 |
| Generic Share | 94 | 1 |
| Annual Cost of Treatment | 95 | 1 |
| Treatment Usage Patterns | 96 | 1 |
| Drivers and Barriers | 97 | 1 |
| Drivers | 98 | 1 |
| Barriers | 98 | 1 |
| Ovarian Cancer | 99 | 1 |
| Introduction | 99 | 1 |
| Survival Rates | 99 | 1 |
| Symptoms | 100 | 1 |
| Treatment Flow | 100 | 1 |
| Revenue | 101 | 1 |
| Geographical Segmentation | 102 | 2 |
| Branded and Generic Drug Share | 104 | 1 |
| Annual Cost of Treatment | 105 | 1 |
| Treatment Usage Patterns | 106 | 1 |
| Drivers and Barriers | 107 | 1 |
| Drivers | 108 | 1 |
| Barriers | 108 | 1 |
| Cervical Cancer | 108 | 1 |
| Introduction | 108 | 1 |
| Survival Rates | 109 | 1 |
| Symptoms | 110 | 1 |
| Treatment Flow | 110 | 1 |
| Revenue | 111 | 1 |
| Geographical Segmentation | 112 | 2 |
| Generic Share | 114 | 1 |
| Annual Cost of Treatment | 115 | 1 |
| Treatment Usage Patterns | 116 | 2 |
| Drivers and Barriers | 118 | 1 |
| Drivers | 118 | 1 |
| Barriers | 118 | 1 |
| Head and Neck Cancer | 119 | 1 |
| Introduction | 119 | 1 |
| Survival Rates | 120 | 1 |
| Symptoms | 120 | 1 |
| Treatment Flow | 121 | 1 |
| Revenue | 122 | 1 |
| Geographical Segmentation | 123 | 2 |
| Generic Share | 125 | 1 |
| Annual Cost of Treatment | 126 | 1 |
| Treatment Usage Patterns | 127 | 2 |
| Drivers and Barriers | 129 | 1 |
| Drivers | 129 | 1 |
| Barriers | 129 | 1 |
| Oncology Therapeutics Market to 2017 - Product Pipeline Analysis | 130 | 56 |
| Introduction | 130 | 2 |
| R&D Pipeline - Breast Cancer | 132 | 9 |
| Promising Drugs in the Pipeline | 141 | 1 |
| T-DM1 | 141 | 1 |
| Afinitor (everolimus) | 141 | 1 |
| NeuVax (E75) | 142 | 1 |
| R&D Pipeline - Colorectal Cancer | 142 | 8 |
| Promising Molecules in the Pipeline | 150 | 1 |
| Aflibercept | 150 | 1 |
| KRX-0401 (perifosine) | 150 | 1 |
| R&D Pipeline - NHL | 151 | 1 |
| Non-Hodgkin s Lymphoma Therapeutics Pipeline | 151 | 5 |
| Promising Pipeline Molecules | 156 | 1 |
| LY317615 | 156 | 1 |
| Obinutuzumab | 156 | 1 |
| R&D Pipeline - NSCLC | 157 | 6 |
| Promising Pipeline Molecules | 163 | 1 |
| Necitumumab (IMC-11F8) | 163 | 1 |
| Tomtovok (Afatinib, BIBW 2992) | 163 | 1 |
| MAGE-A3 | 163 | 1 |
| R&D Pipeline - Prostate Cancer | 164 | 6 |
| Promising Pipeline Molecules | 170 | 1 |
| Aflibercept | 170 | 1 |
| MDX-010 (Ipilimumab) | 170 | 1 |
| R&D Pipeline - Ovarian Cancer | 171 | 7 |
| Promising Pipeline Molecules | 178 | 1 |
| Avastin (Approved in the EU) | 178 | 1 |
| MORAb-003 | 178 | 1 |
| R&D Pipeline - Cervical Cancer | 179 | 2 |
| Promising Pipeline Molecules | 181 | 1 |
| V503 | 181 | 1 |
| R&D Pipeline - Head and Neck Cancer | 181 | 3 |
| Promising Pipeline Products | 184 | 1 |
| Tykerb | 184 | 1 |
| TheraCIM | 184 | 1 |
| Tomtovok | 185 | 1 |
| Pipeline Analysis | 185 | 1 |
| Oncology Therapeutics Market to 2017 - Competitive Landscape | 186 | 7 |
| Market Share Analysis | 186 | 1 |
| Competitive Profiling | 187 | 1 |
| F. Hoffmann-La Roche | 187 | 1 |
| Overview | 187 | 1 |
| AstraZeneca PLC | 188 | 1 |
| Overview | 189 | 1 |
| Eli Lilly and Company | 190 | 1 |
| Overview | 190 | 1 |
| Sanofi | 191 | 1 |
| Overview | 191 | 1 |
| Novartis AG | 192 | 1 |
| Overview | 192 | 1 |
| Oncology Therapeutics Market to 2017 - Strategic Consolidations | 193 | 14 |
| M&A Landscape | 193 | 2 |
| M&A Deals by Year | 195 | 1 |
| M&A Deals by Geography | 196 | 1 |
| M&A Deals by Value | 197 | 1 |
| M&A Deals by Deal Type | 198 | 1 |
| R&D Licensing Agreements | 199 | 1 |
| Deals by Year | 200 | 1 |
| Deals by Geography | 201 | 1 |
| Deals by Value | 202 | 1 |
| Co-Development Agreements | 203 | 1 |
| Deals by Year | 204 | 1 |
| Deals by Geography | 205 | 1 |
| Deals by Value | 206 | 1 |
| Appendix | 207 | 9 |
| Market Definitions | 207 | 1 |
| Abbreviations | 207 | 2 |
| Research Methodology | 209 | 2 |
| Coverage | 209 | 1 |
| Secondary Research | 210 | 1 |
| Primary Research | 210 | 1 |
| Therapeutic Landscape | 211 | 3 |
| Epidemiology-Based Forecasting | 211 | 2 |
| Market Size by Geography | 213 | 1 |
| Geographical Landscape | 214 | 1 |
| Pipeline Analysis | 214 | 1 |
| Competitive Landscape | 214 | 1 |
| Expert Panel Validation | 214 | 1 |
| Contact Us | 214 | 1 |
| Disclaimer | 214 | 1 |
| Sources | 215 | 1 |